Hypolipidemic compound. PPARα (peroxisome proliferator-activated receptor α) agonist (EC50=18µM for mouse and EC50=30µM for human PPARα). Also binds to PPARγ, but with at least 10-fold less affinity and is inactive at PPARδ (up to EC50=100µM).
Product Details
| Alternative Name: | 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methyl-propanoic acid 1-methylethyl ester, Procetofen |
| |
| Formula: | C20H21ClO4 |
| |
| MW: | 360.8 |
| |
| CAS: | 49562-28-9 |
| |
| MI: | 14: 3978 |
| |
| RTECS: | UA2453400 |
| |
| Purity: | ≥98% (GC) |
| |
| Appearance: | White to off-white crystalline solid. |
| |
| Solubility: | Soluble in acetone, ether, DMSO or dimethyl formamide; slightly soluble in 100% ethanol or methanol; insoluble in water. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis and elongation in mice: M.H. Oosterveer, et al.; J. Biol. Chem.
284, 34036 (2009),
Abstract;
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition: D. Panigrahy, et al.; PNAS
105, 985 (2008),
Abstract;
Full Text
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study: S. Pierno, et al.; Br. J. Pharmacol.
149, 909 (2006),
Abstract;
Full Text
In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer: S.A. Saidi, et al.; Mol. Cancer
5, 13 (2006),
Abstract;
Full Text
Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol: E. Chaput, et al.; Lipids
34, 497 (1999),
Abstract;
Inhibition of membrane-bound hepatic 3 hydroxy-3 methyl glutaryl CoA reductase as the consequence of altered membrane fluidity: E. Wulfert, et al.; Artery
9, 120 (1981),
Abstract;
Related Products
